Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Individuals ...
In a phase 3 trial, toripalimab-based chemotherapy with radiotherapy without concurrent cisplatin achieved noninferior 3-year failure-free survival compared with standard therapy in patients with ...
Please provide your email address to receive an email when new articles are posted on . Patients with nasopharyngeal cancer who received morning radiotherapy survived longer than those treated later ...
Reston, VA (June 10, 2025)—A novel immuno-PET/CT imaging technique has identified and validated a potent biomarker for nasopharyngeal cancer (NPC). The biomarker, CD70, is highly and constantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback